Skip to main content
Erschienen in:

22.04.2024 | Hepatozelluläres Karzinom | CME

Diagnostik und Therapie des hepatozellulären Karzinoms

verfasst von: Dr. Melanie Bathon, Anna Saborowski, PD Dr., Arndt Vogel, Prof. Dr.

Erschienen in: Die Gastroenterologie | Ausgabe 3/2024

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Das hepatozelluläre Karzinom (HCC) gehört zu den häufigsten Krebserkrankungen weltweit. Durch die Zunahme der steatotischen Lebererkrankungen zeichnet sich aktuell eine steigende Inzidenz ab, insbesondere in westlichen Ländern. Therapieentscheidungen sollten abhängig von dem Allgemeinzustand des Patienten, der Leberfunktion und dem Tumorstadium getroffen werden und schließen operative Verfahren, wie Lebertransplantation und Resektion, interventionelle Therapien, wie Ablation oder transarterielle Chemoembolisation, bis hin zu verschiedenen systemischen Therapien in fortgeschrittenen Stadien ein. Gerade die systemischen Therapieoptionen haben sich zuletzt durch die Zulassung der Immuntherapien deutlich verbessert. Die multidisziplinäre Betreuung in erfahrenen Zentren mit einem Fokus auf Lebertumoren ist aufgrund der vielfältigen Therapieansätze entscheidend.
Literatur
1.
Zurück zum Zitat Sung H et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209–249CrossRefPubMed Sung H et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209–249CrossRefPubMed
2.
Zurück zum Zitat Siegel, R.L., et al., Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 2022. 72(1): p. 7–33. Siegel, R.L., et al., Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 2022. 72(1): p. 7–33.
3.
Zurück zum Zitat Jinjuvadia, R., S. Patel, and S. Liangpunsakul, The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol, 2014. 48(2): p. 172–7. Jinjuvadia, R., S. Patel, and S. Liangpunsakul, The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol, 2014. 48(2): p. 172–7.
4.
Zurück zum Zitat Dang H et al (2020) Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. Hepatology 71(6):1910–1922CrossRefPubMed Dang H et al (2020) Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. Hepatology 71(6):1910–1922CrossRefPubMed
5.
Zurück zum Zitat Yin J et al (2013) Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 31(29):3647–3655CrossRefPubMed Yin J et al (2013) Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 31(29):3647–3655CrossRefPubMed
7.
Zurück zum Zitat Forner A et al (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47(1):97–104CrossRefPubMed Forner A et al (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47(1):97–104CrossRefPubMed
8.
Zurück zum Zitat Kim YY et al (2019) Hepatocellular Carcinoma versus Other Hepatic Malignancy in Cirrhosis: Performance of LI-RADS Version 2018. Radiology 291(1):72–80CrossRefPubMed Kim YY et al (2019) Hepatocellular Carcinoma versus Other Hepatic Malignancy in Cirrhosis: Performance of LI-RADS Version 2018. Radiology 291(1):72–80CrossRefPubMed
9.
Zurück zum Zitat Silva MA et al (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57(11):1592–1596CrossRefPubMed Silva MA et al (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57(11):1592–1596CrossRefPubMed
10.
Zurück zum Zitat Johnson PJ et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol 33(6):550–558CrossRefPubMed Johnson PJ et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol 33(6):550–558CrossRefPubMed
11.
12.
Zurück zum Zitat Yang JD et al (2019) GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev 28(3):531–538CrossRefPubMed Yang JD et al (2019) GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev 28(3):531–538CrossRefPubMed
14.
Zurück zum Zitat Zhu AX et al (2021) Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer 124(8):1388–1397CrossRefPubMedPubMedCentral Zhu AX et al (2021) Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer 124(8):1388–1397CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Yao FY et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33(6):1394–1403CrossRefPubMed Yao FY et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33(6):1394–1403CrossRefPubMed
16.
Zurück zum Zitat Mazzaferro V et al (2020) Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 21(7):947–956CrossRefPubMed Mazzaferro V et al (2020) Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 21(7):947–956CrossRefPubMed
17.
Zurück zum Zitat Oligane HC, Xing M, Kim HS (2017) Effect of Bridging Local-Regional Therapy on Recurrence of Hepatocellular Carcinoma and Survival after Orthotopic Liver Transplantation. Radiology 282(3):869–879CrossRefPubMed Oligane HC, Xing M, Kim HS (2017) Effect of Bridging Local-Regional Therapy on Recurrence of Hepatocellular Carcinoma and Survival after Orthotopic Liver Transplantation. Radiology 282(3):869–879CrossRefPubMed
18.
Zurück zum Zitat Zhou Y et al (2014) Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: a systematic review. Surg Oncol 23(4):236–242CrossRefPubMed Zhou Y et al (2014) Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: a systematic review. Surg Oncol 23(4):236–242CrossRefPubMed
19.
Zurück zum Zitat Citterio D et al (2016) Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma. JAMA Surg 151(9):846–853CrossRefPubMed Citterio D et al (2016) Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma. JAMA Surg 151(9):846–853CrossRefPubMed
20.
Zurück zum Zitat Hack SP et al (2020) IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol 16(15):975–989CrossRefPubMed Hack SP et al (2020) IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol 16(15):975–989CrossRefPubMed
21.
Zurück zum Zitat Qin S et al (2023) Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 402(10415):1835–1847CrossRefPubMed Qin S et al (2023) Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 402(10415):1835–1847CrossRefPubMed
22.
Zurück zum Zitat Takayama T et al (2022) Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial). Liver Cancer 11(3):209–218CrossRefPubMed Takayama T et al (2022) Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial). Liver Cancer 11(3):209–218CrossRefPubMed
23.
Zurück zum Zitat Brown KT et al (2016) Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol 34(17):2046–2053CrossRefPubMedPubMedCentral Brown KT et al (2016) Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol 34(17):2046–2053CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Chow PKH et al (2018) SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 36(19):1913–1921CrossRefPubMed Chow PKH et al (2018) SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 36(19):1913–1921CrossRefPubMed
25.
Zurück zum Zitat Reig M et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 76(3):681–693CrossRefPubMed Reig M et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 76(3):681–693CrossRefPubMed
26.
Zurück zum Zitat Saborowski, A., et al., IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)—Updated efficacy results. Journal of Clinical Oncology, 2022. 40(16_suppl): p. 4116–4116. Saborowski, A., et al., IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)—Updated efficacy results. Journal of Clinical Oncology, 2022. 40(16_suppl): p. 4116–4116.
27.
Zurück zum Zitat Lencioni R et al (2024) EMERALD-1: A phase 3. randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. Journal of Clinical Oncology, (42(3_suppl): p. LBA432-LBA432.) Lencioni R et al (2024) EMERALD-1: A phase 3. randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. Journal of Clinical Oncology, (42(3_suppl): p. LBA432-LBA432.)
28.
Zurück zum Zitat Finn, R.S., et al., IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 2021. 39(3_suppl): p. 267–267. Finn, R.S., et al., IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 2021. 39(3_suppl): p. 267–267.
29.
Zurück zum Zitat Galle PR et al (2021) Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol 22(7):991–1001CrossRefPubMed Galle PR et al (2021) Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol 22(7):991–1001CrossRefPubMed
30.
Zurück zum Zitat Abou-Alfa, G.K., et al., Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Journal of Clinical Oncology, 2022. 40(4_suppl): p. 379–379. Abou-Alfa, G.K., et al., Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Journal of Clinical Oncology, 2022. 40(4_suppl): p. 379–379.
Metadaten
Titel
Diagnostik und Therapie des hepatozellulären Karzinoms
verfasst von
Dr. Melanie Bathon
Anna Saborowski, PD Dr.
Arndt Vogel, Prof. Dr.
Publikationsdatum
22.04.2024

Weitere Artikel der Ausgabe 3/2024

Die Gastroenterologie 3/2024 Zur Ausgabe

Mitteilungen der Stiftung LebensBlicke

Mitteilungen der Stiftung LebensBlicke

Abstracts der Gesellschaft für Gastroenterologie in NRW

Abstracts Viszeralmedizin NRW 2024

Einführung zum Thema

Klinische Pathologie